Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature

Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature

The coexistence of three or more transcripts in one patient with chronic myeloid leukemia (CML) is rarely reported. Thus, the disease progression and drug response are still unknown. This case report aimed to explore the drug response of CML with variant transcripts and to enrich the clinical treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Xu, Yuying Fan, Sijin Liu, Jianmei Chang, Caifeng Guo, Lanhui Chen, Wenzheng Guo, Jinwen Dang, Hongwei Wang, Yanhong Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
chronic myelogenous leukemia
BCR::ABL1
e16a2 transcripts
variant transcript
tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1518387/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coexistence of three or more transcripts in one patient with chronic myeloid leukemia (CML) is rarely reported. Thus, the disease progression and drug response are still unknown. This case report aimed to explore the drug response of CML with variant transcripts and to enrich the clinical treatment of rare types of CML. A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four BCR::ABL1 transcripts, including variant e16a2(V-e16a2), variant e13a2(V-e13a2), classical e13a2, and e14a2 transcripts. The patient was treated with flumatinib, a tyrosine kinase inhibitor (TKI).The variant transcripts reported exhibited a favorable response to TKI, and attention should be directed toward monitoring variant transcripts.
ISSN:2234-943X

Similar Items